Efficacy of holmium laser enucleation in patients with a small (less than 30 mL) prostate volume.
Enucleation
Holmium
Laser therapy
Prostatic hyperplasia
Transurethral resection of prostate
Journal
Investigative and clinical urology
ISSN: 2466-054X
Titre abrégé: Investig Clin Urol
Pays: Korea (South)
ID NLM: 101674989
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
05
10
2020
revised:
09
12
2020
accepted:
04
01
2021
entrez:
4
5
2021
pubmed:
5
5
2021
medline:
9
2
2022
Statut:
ppublish
Résumé
To evaluate the efficacy of holmium laser enucleation of the prostate (HoLEP) in patients with a small prostate volume (≤30 mL). We retrospectively evaluated 1,135 patients who underwent HoLEP at two institutions between July 2007 and March 2020. Patients who were not evaluated for the International Prostate Symptom Score (IPSS) before or after HoLEP were excluded. We divided patients into two groups according to estimated prostate volume (ePV): ≤30 (n=198) and >30 mL (n=539). The patient characteristics, IPSS, peak urinary flow rate (Qmax), postvoid residual urine volume (PVR), and other data were compared before and after surgery in each group and between the two groups. Multivariate analysis was performed to identify the factors associated with the efficacy of HoLEP in the group with ePV ≤30 mL. A total of 737 patients were included in this retrospective study. ePV (23.4 mL vs. 50 mL; p<0.001) and PVR differed significantly between the two groups. The IPSS, IPSS-quality of life, PVR, and Qmax significantly improved after HoLEP in both groups. Improvements in the IPSS, IPSS-quality of life, Qmax, and PVR were greater in the >30 mL group (p<0.001), whereas operation time and morcellation time were significantly shorter in the ≤30 mL group. In the multivariate analysis, age <70 years was independently associated with improvement by HoLEP. HoLEP is an effective treatment for patients with a small prostate, even though the extent of improvement after HoLEP was greater in those with a larger prostate.
Identifiants
pubmed: 33943050
pii: 62.298
doi: 10.4111/icu.20200450
pmc: PMC8100012
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
298-304Informations de copyright
© The Korean Urological Association, 2021.
Déclaration de conflit d'intérêts
The author has nothing to disclose.
Références
Rev Urol. 2005;7 Suppl 9:S3-S14
pubmed: 16985902
Urology. 2009 Jan;73(1):95-9
pubmed: 18952269
J Urol. 2011 Nov;186(5):1972-6
pubmed: 21944127
Urology. 2018 Oct;120:9-22
pubmed: 30403609
BJU Int. 2012 Oct;110(7):1023-9
pubmed: 22233355
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
N Engl J Med. 2003 Dec 18;349(25):2387-98
pubmed: 14681504
Int J Urol. 2020 Jan;27(1):47-52
pubmed: 31542892
Low Urin Tract Symptoms. 2020 May;12(2):117-122
pubmed: 31573756
Urology. 2014 Feb;83(2):428-32
pubmed: 24231217
World J Mens Health. 2017 Dec;35(3):163-169
pubmed: 29164833
Int J Urol. 2017 Oct;24(10):716-729
pubmed: 28748576
World J Urol. 2021 Jan;39(1):129-134
pubmed: 32206890
Urology. 2016 Nov;97:208-211
pubmed: 27450935
J Urol. 2005 Nov;174(5):1887-91
pubmed: 16217330
BJU Int. 2020 Jul;126(1):177-182
pubmed: 32020749
Investig Clin Urol. 2016 Nov;57(6):437-441
pubmed: 27847918
Nat Rev Dis Primers. 2016 May 05;2:16031
pubmed: 27147135
Prostate. 2011 May;71(6):597-603
pubmed: 20945406
World J Mens Health. 2013 Apr;31(1):64-9
pubmed: 23658868